---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-041897"
form_type: "8-K"
ticker: "WAT"
cik: "0001000697"
company_name: "WATERS CORP /DE/"
filed_at: "2026-02-09T23:59:59+00:00"
generated_at: "2026-05-16T03:47:53.688235+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Waters Q4 2025 sales $932M (+7%), non-GAAP EPS $4.53 (+10%); BD deal closed; guides FY26 rev $6.4-6.5B, EPS $14.30-14.50

## Summary
- Q4 sales $932M (+7% reported, +6% CC); GAAP EPS $3.77, non-GAAP EPS $4.53 (+10% YoY).
- Q4 end-markets: Pharma +8%, Industrial +8%, Academic/Gov -2%; Instruments +3%, Recurring +10% (Chemistry +12% CC).
- Full-year 2025 sales $3,165M (+7%); non-GAAP EPS $13.13 (+11% YoY).
- Closes BD Biosciences & Diagnostic Solutions acquisition; acquired business adds ~$3.0B revenue in FY2026.
- FY2026 guidance: organic CC growth 5.5%-7.0%, total rev $6.405B-$6.455B; non-GAAP EPS $14.30-$14.50 (+8.9%-10.4% YoY).

## SEC filing metadata
- accession: 0001193125-26-041897
- form_type: 8-K
- ticker: WAT
- cik: 0001000697
- company_name: WATERS CORP /DE/
- filed_at: 2026-02-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000697/000119312526041897/0001193125-26-041897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000697/000119312526041897/d37473d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-041897
- JSON: https://secwatch.observer/filing/0001193125-26-041897.json
- Plain text: https://secwatch.observer/filing/0001193125-26-041897.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.